FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner NDI warning letters fuel criticism of FDA enforcement approach Regulation of Dietary Supplements and Other Specialized Categories On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a Warning Letter to Platinum Biologics LLC for marketing umbilicalcordderived products including exosome products (NanoEx & Nano Xsomes) without approval. As unregulated peptides grow in popularity, doctors warn of unknown risks ABC30 Fresno FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures